CuraTeQ Biologics Secures Health Canada NOC for Bevqolva™ Bevacizumab Biosimilar

CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Ltd, has received Notice of Compliance (NOC) from Health Canada's Biologics and Radiopharmaceutical Drugs Directorate (BRDD) for Bevqolva™, its bevacizumab biosimilar. Health Canada issues an NOC after a successful review, granting formal marketing authorization to the biosimilar by confirming it meets regulatory standards for safety, efficacy, and quality - comparable to the reference biologic drug under the Food and Drug Regulations.

Bevacizumab, a humanized monoclonal antibody, inhibits angiogenesis - the formation of new blood vessels - by blocking vascular endothelial growth factor A (VEGF-A). This action slows tumor vascular growth and treats multiple cancers, including colorectal and lung. Available in 100 mg and 400 mg formulations, the originator product Avastin is marketed by Roche/Genentech.

In 2025, Bevqolva™ secured marketing authorization from the MHRA and launched commercially for patients across the UK. The product is currently under review by the CHMP with the European Medicines Agency. CuraTeQ Biologics also has two additional biosimilar applications under review by Health Canada.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1389.55 as compared to the previous close of Rs. 1396.50. The total number of shares traded during the day was 16117 in over 1464 trades.

The stock hit an intraday high of Rs. 1401.30 and intraday low of 1378.80. The net turnover during the day was Rs. 22427118.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 Pharmaceuticals CuraTeQBiologics HealthCanada NOC Bevqolva Bevacizumab Biosimilar